Phase 2 Study of Twice Weekly VELCADE and CAELYX in Patients With Ovarian Cancer Failing Platinum Containing Regimens

PHASE2WithdrawnINTERVENTIONAL
Enrollment

91

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

September 30, 2009

Conditions
Ovarian Cancer
Interventions
DRUG

bortezomib

1.3 mg/m2 on Days 1, 4, 8 \& 11 every 3 weeks (1 cycle = 21 days) for up to six cycles

DRUG

pegylated liposomal doxorubicin

30 mg/m2 on Day 1 every 3 weeks (1 cycle = 21 days) for up to six cycles

Trial Locations (7)

Unknown

Division of Gynecologic Oncology, Università Catholica Sacre Cuore, Campbasso

Istituto Europeo di Oncologia (IEO), Milan

Istituto Nazionale dei Tumori, Milan

Dept. Procreational Medicine, Università di Pisa, Pisa

Kantonsspital St. Gallen, Sankt Gallen

Gynecologic Oncology Unit, Ospedale Sant' Anna

Istituto Oncologico della Svizzera Italiana, Bellinzona

All Listed Sponsors
lead

Millennium Pharmaceuticals, Inc.

INDUSTRY